News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Sanofi-Aventis (France) Buys U.S. Cancer Firm, BiPar Sciences, Inc. for up to $500 Million
April 15, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Sanofi-Aventis has agreed to buy private U.S. cancer specialist BiPar Sciences Inc. for up to $500 million in the latest bolt-on acquisition by the French drugmaker.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Mergers & acquisitions
Europe
Sanofi (France)
MORE ON THIS TOPIC
Layoffs
Genentech Downsizes by 87 as Priorities Shift
July 24, 2025
·
2 min read
·
Tristan Manalac
Obesity
Roche Drops Early Obesity Asset, Citing Lack of Competitiveness
July 24, 2025
·
2 min read
·
Tristan Manalac
Business
Maryland’s Life Sciences Scene Boasts Strong R&D, Manufacturing Talent
July 24, 2025
·
4 min read
·
Angela Gabriel
Startups
Dispatch Bio Launches With $216M To Develop Universal CAR T Therapy for Solid Tumors
July 23, 2025
·
2 min read
·
Tristan Manalac
